News

Find News

Filter articles

Showing 31 to 40 of 2614 results

Teva to pay California $69m over pay-for-delay deals

US30-07-2019Saman Javed

The state of California has secured a $69 million settlement with Teva, which allegedly entered into collusive pay-for-delay agreements with generic competitors.

Federal Circuit dismisses Amgen’s Neulasta appeal

US30-07-2019

California-based Amgen is barred from succeeding on its patent infringement claim against Coherus Biosciences, according to the US Court of Appeals for the Federal Circuit.

Pfizer off-patent division to merge with Mylan

UK29-07-2019Rory O'Neill

Pfizer is to merge its off-patent drug business Upjohn with Mylan, in a deal that will see Pfizer shareholders own 57% of the new company.

Bio-Rad wins injunction against 10X Genomics

US26-07-2019Sarah Morgan

Bio-Rad, a developer of clinical diagnostic products, secured a permanent injunction against a competitor earlier this week in a long-running dispute.

Celgene settles antitrust class-action for $55m

US25-07-2019Saman Javed

US biotech company Celgene has agreed to pay a $55 million settlement after it was accused of illegally maintaining a monopoly over the market for its cancer treatments.

Vaccines growth offsets Advair generic pain for GSK

UK25-07-2019Sarah Morgan

Growth in GlaxoSmithKline’s vaccines and consumer healthcare divisions has managed to partly counter the impact of generic versions of Advair on its sales.

Gilead licenses HIV injections for $25m

US24-07-2019Rory O'Neill

Gilead has obtained exclusive worldwide rights to market a long-acting injectable HIV product based on Durect Corporation’s Saber technology.

FDA opens US to Lyrica generics

US24-07-2019Sarah Morgan

The US Food and Drug Administration last week approved nine applications for the first generic versions of Pfizer’s Lyrica.

UK High Court rules Roche patent is invalid

UK23-07-2019Saman Javed

The English High Court has ruled that a patent owned by Roche should be revoked on grounds of insufficiency.

Sigma-Aldrich submits CRISPR petition at USPTO

US23-07-2019Sarah Morgan

Merck KGaA-owned Sigma-Aldrich has petitioned the US Patent and Trademark Office to open an interference proceeding between its own pending CRISPR-Cas9 patents and patents awarded to the University of California, Berkeley.

Showing 31 to 40 of 2614 results

LSIPR